Viridian Therapeutics (VRDN) to Post Earnings on Wednesday

Viridian Therapeutics (NASDAQ:VRDN) is expected to be issuing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Viridian Therapeutics to announce earnings of ($1.02) per share and revenue of $0.0310 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.90) earnings per share for the quarter, topping the consensus estimate of ($1.06) by $0.16. Viridian Therapeutics had a negative return on equity of 80.19% and a negative net margin of 490.31%.The company had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.04 million. During the same quarter last year, the business posted ($0.87) earnings per share. Viridian Therapeutics’s revenue was up 95.8% compared to the same quarter last year. On average, analysts expect Viridian Therapeutics to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Viridian Therapeutics Price Performance

Shares of NASDAQ:VRDN opened at $18.92 on Monday. The company has a quick ratio of 15.15, a current ratio of 15.15 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $1.95 billion, a P/E ratio of -5.70 and a beta of 0.90. Viridian Therapeutics has a 52-week low of $13.18 and a 52-week high of $34.29. The stock’s fifty day simple moving average is $17.97 and its 200-day simple moving average is $21.99.

Insider Buying and Selling at Viridian Therapeutics

In other news, Director Fairmount Funds Management Llc bought 1,176,470 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was acquired at an average price of $17.00 per share, for a total transaction of $19,999,990.00. Following the acquisition, the director owned 5,090,928 shares of the company’s stock, valued at $86,545,776. This trade represents a 30.05% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 2.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Viridian Therapeutics

Large investors have recently made changes to their positions in the business. Morgan Stanley grew its stake in shares of Viridian Therapeutics by 805.6% in the fourth quarter. Morgan Stanley now owns 1,738,225 shares of the company’s stock valued at $54,094,000 after buying an additional 1,546,284 shares in the last quarter. Commodore Capital LP lifted its position in Viridian Therapeutics by 35.4% during the 2nd quarter. Commodore Capital LP now owns 4,875,000 shares of the company’s stock worth $68,152,000 after acquiring an additional 1,275,000 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Viridian Therapeutics by 42.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,439,414 shares of the company’s stock worth $107,036,000 after acquiring an additional 1,021,310 shares in the last quarter. State Street Corp boosted its holdings in Viridian Therapeutics by 35.7% in the 4th quarter. State Street Corp now owns 3,466,560 shares of the company’s stock worth $107,879,000 after acquiring an additional 912,394 shares during the period. Finally, Wellington Management Group LLP boosted its holdings in Viridian Therapeutics by 314.9% in the 3rd quarter. Wellington Management Group LLP now owns 1,122,532 shares of the company’s stock worth $24,224,000 after acquiring an additional 851,989 shares during the period.

Analyst Upgrades and Downgrades

VRDN has been the subject of several analyst reports. The Goldman Sachs Group reissued a “buy” rating and issued a $39.00 target price on shares of Viridian Therapeutics in a research note on Tuesday, June 30th. Weiss Ratings lowered shares of Viridian Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. Wall Street Zen downgraded shares of Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday. Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 target price on shares of Viridian Therapeutics in a research note on Monday, June 29th. Finally, Truist Financial boosted their price target on Viridian Therapeutics from $35.00 to $38.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Thirteen equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $38.79.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.